JP2008501716A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501716A5
JP2008501716A5 JP2007515646A JP2007515646A JP2008501716A5 JP 2008501716 A5 JP2008501716 A5 JP 2008501716A5 JP 2007515646 A JP2007515646 A JP 2007515646A JP 2007515646 A JP2007515646 A JP 2007515646A JP 2008501716 A5 JP2008501716 A5 JP 2008501716A5
Authority
JP
Japan
Prior art keywords
medicament
syndrome
disease
autoinflammatory
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501716A (ja
JP5022216B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019674 external-priority patent/WO2005117945A1/en
Publication of JP2008501716A publication Critical patent/JP2008501716A/ja
Publication of JP2008501716A5 publication Critical patent/JP2008501716A5/ja
Application granted granted Critical
Publication of JP5022216B2 publication Critical patent/JP5022216B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515646A 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法 Expired - Fee Related JP5022216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57702304P 2004-06-04 2004-06-04
US60/577,023 2004-06-04
PCT/US2005/019674 WO2005117945A1 (en) 2004-06-04 2005-06-03 Methods of using il-1 antagonists to treat autoinflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012012800A Division JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Publications (3)

Publication Number Publication Date
JP2008501716A JP2008501716A (ja) 2008-01-24
JP2008501716A5 true JP2008501716A5 (cg-RX-API-DMAC7.html) 2008-04-24
JP5022216B2 JP5022216B2 (ja) 2012-09-12

Family

ID=34972252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515646A Expired - Fee Related JP5022216B2 (ja) 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Country Status (9)

Country Link
US (4) US7459426B2 (cg-RX-API-DMAC7.html)
EP (1) EP1750746A1 (cg-RX-API-DMAC7.html)
JP (2) JP5022216B2 (cg-RX-API-DMAC7.html)
CN (1) CN1964737B (cg-RX-API-DMAC7.html)
AU (1) AU2005249570B2 (cg-RX-API-DMAC7.html)
CA (1) CA2568352C (cg-RX-API-DMAC7.html)
IL (1) IL179512A0 (cg-RX-API-DMAC7.html)
MX (2) MXPA06014126A (cg-RX-API-DMAC7.html)
WO (1) WO2005117945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
WO2006076673A2 (en) * 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
EP2124997B1 (en) * 2006-10-20 2012-08-08 Regeneron Pharmaceuticals, Inc. Use of il-1 antagonists to treat gout and pseudogout
US7632490B2 (en) 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
US20080227709A1 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
KR102606597B1 (ko) 2007-05-29 2023-11-29 노파르티스 아게 항-ｉｌ-1-베타 치료법에 대한 신규 적응증
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HRP20191494T1 (hr) * 2012-03-31 2019-11-29 R Pharm Int Llc Pripravak derivat osteoprotegerina i njegova uporaba
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
KR102236926B1 (ko) 2013-03-13 2021-04-06 세센 바이오, 아이엔씨. 안구 운반을 위한 키메릭 사이토카인 제제
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
HK1225742A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
JP6565099B2 (ja) * 2015-09-18 2019-08-28 国立大学法人 長崎大学 家族性地中海熱のバイオマーカー
RU2022102624A (ru) * 2015-10-01 2022-03-10 Хит Байолоджикс, Инк. Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков
KR20180134880A (ko) * 2016-03-09 2018-12-19 슈 생-쥐스땡 주산기 이환율 및/또는 사망률을 감소시키는 방법
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
BR112019020373A2 (pt) * 2017-04-03 2020-04-28 Wisconsin Alumni Research Foundation micropartículas revestidas com minerais para liberação sustentada de moléculas biologicamente ativas
JP2022524178A (ja) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法
WO2021089782A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment of autoinflammatory disorders
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
WO2021184128A1 (en) * 2020-03-20 2021-09-23 Institut De Cardiologie De Montreal Methods of treating a coronavirus infection using colchicine
US20230210792A1 (en) * 2020-06-05 2023-07-06 Aristea Therapeutics, Inc. Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
NZ538569A (en) * 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization

Similar Documents

Publication Publication Date Title
JP2008501716A5 (cg-RX-API-DMAC7.html)
CA2568352A1 (en) Methods of using il-1 antagonists to treat autoinflammatory disease
Malcova et al. IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives
Assier et al. Interleukin-6: from identification of the cytokine to development of targeted treatments
Nishimoto Interleukin‐6 as a therapeutic target in candidate inflammatory diseases
ES2660036T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
Izuhara et al. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies
JP2011507891A5 (cg-RX-API-DMAC7.html)
CN1322897C (zh) Il－18抑制剂的应用
JP2017079785A5 (cg-RX-API-DMAC7.html)
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
HRP20150790T1 (hr) Režimi imunoterapije koji ovise o statusu apoe
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
Lopalco et al. Canakinumab efficacy in refractory adult-onset PFAPA syndrome.
NZ597915A (en) Combination therapy for treatment of immune disorders
IL171866A (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, PROCESS FOR THEIR PREPARATION AND ARTICLES OF MANUFACTURE COMPRISING THEM
JP2012070740A5 (cg-RX-API-DMAC7.html)
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
US10456456B2 (en) Anti-IL-6 vaccine composition
Nishimoto Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan
McDermott Rilonacept in the treatment of chronic inflammatory disorders
Finckh et al. At the horizon of innovative therapy in rheumatology: new biologic agents
Çakan et al. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases
Scharl et al. new anti-cytokines for IBD: what is in the pipeline?
JP2006508039A5 (cg-RX-API-DMAC7.html)